Document is current

Article History

Received: 13 April 2025

Accepted: 13 July 2025

First Online: 22 July 2025

Declarations

:

: This study protocol was reviewed and approved by the local ethics committee of the Hospices Civils de Lyon (Comité Scientifique et Éthique des Hospices Civils de Lyon), IRB (Internal Review Board) 00013204, AGORA number 23-5439.

: Informed consent was obtained from all the participants/legal guardian of participants prior to the study, to use their data in a completely anonymized form. Written informed consent was not deemed necessary because the study was conducted using regularly collected data. This study protocol and consent procedure was reviewed and approved by the local ethics committee of the Hospices Civils de Lyon (Comité Scientifique et Éthique des Hospices Civils de Lyon, Lyon, France), approval numbers IRB (Internal Review Board) 00013204, AGORA number 23-5439 (conformité MR004 n°23-5439), decision date 20/05/2024, and non-opposition was collected from patients. The study was in line with local and national guidelines.Our study has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

: C. de Laurentis declares that she has no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.S. Thobois declares honoraria from Boston, Medtronic, Abbvie, Merz, NHC, MDS for consulting, board, or conferences; meeting and travel grant from the MDS and Abbvie.T. Danaila declares honoraria from Abbvie and Orkyn.C. Laurencin declares travel grants from Abbvie, and honoraria from Orphalan.G. Polo declares that he has no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.S. Prange declares honoraria from Abbvie for consulting.E. Simon declares honoraria from Boston & BrainLab for conferences, meeting and travel grant from Boston.